Buprenorphine

Generic Name
Buprenorphine
Brand Names
Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
Drug Type
Small Molecule
Chemical Formula
C29H41NO4
CAS Number
52485-79-7
Unique Ingredient Identifier
40D3SCR4GZ
Background

Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...

Indication

Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...

Associated Conditions
Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
Associated Therapies
-
Clinical Trials
Related News

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

First Posted Date
1999-09-21
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
202
Registration Number
NCT00000318
Locations
🇺🇸

APT Residential Services Division, New Haven, Connecticut, United States

Effects of Buprenorphine and Naloxone in Opiate Addicts - 4

First Posted Date
1999-09-21
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000355
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone

Not Applicable
Terminated
Conditions
Opioid-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
16
Registration Number
NCT00000243
Locations
🇺🇸

Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States

Buprenorphine Dosing Interval - 5

Phase 2
Completed
Conditions
Opioid-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2005-08-17
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000209
Locations
🇺🇸

Friends Research Institute, Los Angeles, California, United States

Methadone/Buprenorphine Cross-Over Study - 4

Phase 2
Completed
Conditions
Opioid-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2005-08-17
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000208
Locations
🇺🇸

Friends Research Institute, Los Angeles, California, United States

Comparison of Buprenorphine and Methadone - 3

Phase 2
Completed
Conditions
Opioid-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2017-01-31
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000334
Locations
🇺🇸

Washington DC VA, Washington, District of Columbia, United States

Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

Phase 3
Completed
Conditions
Heroin Dependence
First Posted Date
1999-09-21
Last Posted Date
2005-11-07
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000302
Locations
🇺🇸

Friends Research Institute, Los Angeles, California, United States

Buprenorphine Detox With Two Types of Treatment. BBD I - 10

Phase 2
Completed
Conditions
Opioid-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2005-08-17
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000228
Locations
🇺🇸

Treatment Research Center, Burlington, Vermont, United States

Clinical Rescue Protocol - 2

Phase 2
Completed
Conditions
Opioid-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2016-11-06
Lead Sponsor
University of California, Los Angeles
Registration Number
NCT00000206
Locations
🇺🇸

Friends Research Institute, Los Angeles, California, United States

Alternate Day Buprenorphine Administration, Phase IX - 14

Phase 2
Completed
Conditions
Opioid-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2016-05-06
Lead Sponsor
University of Vermont
Registration Number
NCT00000232
Locations
🇺🇸

Treatment Research Center, Burlington, Vermont, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy